Chonluten
Glu-Asp-Gly Bronchial Bioregulator
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
Support rests on Khavinson-group animal, in-vitro and mechanistic work plus unreplicated Russian clinical observations; the tripeptide Glu-Asp-Gly (Chonluten) has been shown to attenuate LPS-induced TNF production in THP-1 monocytes (Fedoreyeva group, 2022) and is named alongside Bronchogen in the Khavinson 2020 Molecules COVID-19 review as an oral agent associated with chronic bronchitis and COPD outcomes, but no independently registered human randomized controlled trial supports any respiratory indication. This is an unapproved research chemical, so the honest grade is 1 (animal/in-vitro plus uncontrolled human observation), corrected down from the entry's 2.
- FDA
- Not approved by FDA for any indication; sold only as a research chemical labeled not for human consumption
- WADA
- Not specifically named on the WADA Prohibited List; status is not equivalent to approval or safety clearance
Reference only. Not medical advice.
What can go wrong
Unapproved research chemical with no independent human RCT; evidence is Khavinson-group preclinical plus unreplicated Russian clinical observation.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Chonluten. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
A Khavinson tripeptide targeting bronchial and lung epithelial tissue. Russian data on respiratory function in aging.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Chonluten is a synthetic tripeptide (glutamic acid, aspartic acid, glycine) directed at the lungs and bronchial tissue, promoted for respiratory support in the bioregulator framework. Its proposed mechanism is unproven in controlled human studies.
Chonluten is a synthetic short peptide, a defined-sequence second-generation bioregulator aimed at respiratory tissue, closely related in purpose to the bronchial peptide Bronchogen.
- Type
- Synthetic short peptide
- Target
- Lungs and airways
- Generation
- Second (defined)
- Use
- Pulsed courses
- Evidence
- Preclinical and Russian
- Western RCT
- None
The Lung Label On A Single-Lineage Peptide System
Chonluten repeats the family pattern. Its proposed action is direct peptide-driven gene regulation in respiratory tissue, unestablished outside the originating group, and its lung and mucosal claims are preclinical and Russian without independent human trials. It overlaps heavily with Bronchogen, the bronchial-labeled peptide, which underscores how the system multiplies closely related organ labels on one shared evidence base.
Safety in detail
No independently registered human trial establishes efficacy or a safety profile for Chonluten. Injectable research-chemical peptides carry sterility, contamination and mislabeling risks, and the available human data are uncontrolled Russian reports that have not been replicated by independent groups.
- Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
- Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
- Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
- Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.
Children and teenagers
Chonluten has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Chonluten reaches users only through the bioregulator gray market and longevity vendors, with no approved product.
How we got here
Chonluten descends from the Soviet-era Khavinson program at the St Petersburg Institute of Bioregulation and Gerontology, where natural peptide complexes were extracted from animal bronchial and lung tissue (the cytomax/cytamin class) and then reduced to defined synthetic short peptides (the cytogen class). The natural bronchial complex was rendered as the synthetic tripeptide Glu-Asp-Gly, named Chonluten, while the parallel synthetic tetrapeptide Ala-Glu-Asp-Leu was named Bronchogen; the two share the bronchial-epithelium target and are frequently conflated in vendor marketing. Outside Russia it has no trade approval and circulates only as a research chemical under the Chonluten name and its EDG sequence.
Chonluten was developed as a defined-sequence organ bioregulator at the St. Petersburg institute, extending Khavinson’s approach to the respiratory system alongside Bronchogen.
The numbers behind the grade
- Type
- Tripeptide (Glu-Asp-Gly)
- Target
- Lungs / bronchi
- Russia
- Bioregulator line
- FDA
- Not approved
- Evidence
- Single-tradition
- Western RCTs
- None
The people taking it
A respiratory bioregulator within the Cytogen line, used by a small longevity audience.
Chonluten’s users are respiratory-health and longevity enthusiasts within the bioregulator-protocol community.
Used as a respiratory-support bioregulator within Russian-tradition protocols; evidence is not independently confirmed.
Set against the alternatives
Chonluten is the lung counterpart that overlaps with the bronchial peptide Bronchogen, sharing the family’s framing applied to the respiratory system. Its support is preclinical and single-lineage.
What we do not know
- Whether independent, Western randomized trials confirm any of the claimed clinical effects.
- Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
- Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
- Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.
Legal status
Not FDA-approved for any indication in the United States. Several related bioregulators are registered pharmaceuticals in Russia, where they are used clinically, but that approval does not carry to the US or EU. The first formal FDA advisory-committee evaluation of a Khavinson peptide (Epitalon) is scheduled for July 2026. Internationally it is sold as a Cytogen or Cytomax supplement and as a research chemical.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.
Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Chonluten.
- Timeline. We have not built the dated record of research and regulatory events.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
Sources
Chonluten is the synthetic tripeptide Glu-Asp-Gly (EDG), a bronchial/respiratory bioregulator, and it attenuated LPS-induced TNF production in THP-1 monocytes/macrophages in vitro
Khavinson names oral EDG tripeptide (Chonluten) and AEDL tetrapeptide (Bronchogen) as associated with treatment of bronchopulmonary pathology (COPD, chronic bronchitis with asthmatic component) and proposes them as candidate adjuvant agents for COVID-19 lung damage; no human RCT is reported
Same 2020 Molecules review, publisher landing page confirming citation and open-access status
Khavinson short peptides (2 to 7 residues), including tissue-specific tri/tetrapeptides, are proposed to penetrate cell nuclei and regulate gene expression; foundational mechanism framing for the bioregulator family that includes Chonluten
Systematic review of peptide regulation of gene expression cataloguing Khavinson short peptides and their proposed epigenetic mechanism
Peptide Regulation of Gene Expression: A Systematic Review, Molecules 2021, 26(22):7053
Chonluten placed within the Khavinson bioregulator family (with Epithalon, Cortagen, Pinealon); history of Soviet/Russian development at the St Petersburg Institute of Bioregulation and Gerontology
Khavinson Peptide Bioregulators complete list, Rebel Peptides
Chonluten sold as a research-only lyophilized peptide, not for human consumption; vendor listing documenting research-chemical status, EDG sequence and 20mg format
Independent evidence-and-safety profile stating no clinical data specific to Chonluten have been published and that human RCT evidence is absent
PeptideInsight, Chonluten research evidence and safety profile
Chonluten characterized as a bronchial/lung mucosa bioregulator (EDG tripeptide) in the research-peptide catalogue; corroborates class and target tissue
The studies that matter
Khavinson group studies2000s
Reported respiratory-tissue effects within the bioregulator research program.
Independent replicationnone notable
No independent Western trials of Chonluten exist.